Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The 42nd Annual Meeting of The American Society of Clinical Oncology (ASCO)

The 42nd Annual Meeting of The American Society of Clinical Oncology (ASCO) Am J Cancer 2006; 5 (4): 273-284 MEETING REPORT 1175-6357/06/0004-0273/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. The 42nd Annual Meeting of The American Society of Clinical Oncology (ASCO) 2–6 June 2006, Atlanta, Georgia, USA William Stow and Michelle I. Wilde Adis International Inc., Yardley, Pennsylvania, USA The 42nd Annual Meeting of the American Society of Clinical Addition of lapatinib to capecitabine almost doubles time to Oncology (ASCO) was held in Atlanta, Georgia, USA, in June progression compared with capecitabine alone in women with 2006. This year’s theme was ‘Advocating Survivorship, Clinical HER2-positive, trastuzumab-refractory, advanced breast cancer, Science, and Oncology Quality Care’. ASCO is always a highlight according to interim results of the EGF100151 trial that were on oncologists’ calendars and is consistently a premier source of presented as late-breaking data at a scientific special session by Dr high-impact clinical trial data. Interest was particularly high this Charles Geyer of Allegheny General Hospital (Pittsburgh, PA, year in the treatment of patients who have become refractory to USA). This international, randomized, phase III trial enrolled 392 existing medications. There were >4400 abstracts presented; this women, 321 of whom were evaluable for the primary endpoint of represents a 12–15% http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

The 42nd Annual Meeting of The American Society of Clinical Oncology (ASCO)

American Journal of Cancer , Volume 5 (4) – Aug 9, 2012

Loading next page...
 
/lp/springer-journals/the-42nd-annual-meeting-of-the-american-society-of-clinical-oncology-MYsE3G8B2y

References (62)

Publisher
Springer Journals
Copyright
Copyright © 2006 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200605040-00006
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2006; 5 (4): 273-284 MEETING REPORT 1175-6357/06/0004-0273/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. The 42nd Annual Meeting of The American Society of Clinical Oncology (ASCO) 2–6 June 2006, Atlanta, Georgia, USA William Stow and Michelle I. Wilde Adis International Inc., Yardley, Pennsylvania, USA The 42nd Annual Meeting of the American Society of Clinical Addition of lapatinib to capecitabine almost doubles time to Oncology (ASCO) was held in Atlanta, Georgia, USA, in June progression compared with capecitabine alone in women with 2006. This year’s theme was ‘Advocating Survivorship, Clinical HER2-positive, trastuzumab-refractory, advanced breast cancer, Science, and Oncology Quality Care’. ASCO is always a highlight according to interim results of the EGF100151 trial that were on oncologists’ calendars and is consistently a premier source of presented as late-breaking data at a scientific special session by Dr high-impact clinical trial data. Interest was particularly high this Charles Geyer of Allegheny General Hospital (Pittsburgh, PA, year in the treatment of patients who have become refractory to USA). This international, randomized, phase III trial enrolled 392 existing medications. There were >4400 abstracts presented; this women, 321 of whom were evaluable for the primary endpoint of represents a 12–15%

Journal

American Journal of CancerSpringer Journals

Published: Aug 9, 2012

There are no references for this article.